457 related articles for article (PubMed ID: 18832518)
1. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort.
Schnitzler F; Fidder H; Ferrante M; Noman M; Arijs I; Van Assche G; Hoffman I; Van Steen K; Vermeire S; Rutgeerts P
Gut; 2009 Apr; 58(4):492-500. PubMed ID: 18832518
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.
Sokol H; Seksik P; Carrat F; Nion-Larmurier I; Vienne A; Beaugerie L; Cosnes J
Gut; 2010 Oct; 59(10):1363-8. PubMed ID: 20587545
[TBL] [Abstract][Full Text] [Related]
3. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
4. A pilot study comparing hydrocortisone premedication to concomitant azathioprine treatment in preventing loss of response to infliximab.
Mantzaris GJ; Viazis N; Petraki K; Papamichael K; Theodoropoulos I; Roussos A; Karakoidas C; Koilakou S; Raptis N; Smyrnidis A; Agalos G; Karamanolis DG
Eur J Gastroenterol Hepatol; 2009 Sep; 21(9):1042-8. PubMed ID: 20139856
[TBL] [Abstract][Full Text] [Related]
5. 12-month follow-up after successful infliximab therapy in pediatric crohn disease.
Wynands J; Belbouab R; Candon S; Talbotec C; Mougenot JF; Chatenoud L; Schmitz J; Cézard JP; Goulet O; Hugot JP; Ruemmele FM
J Pediatr Gastroenterol Nutr; 2008 Mar; 46(3):293-8. PubMed ID: 18376247
[TBL] [Abstract][Full Text] [Related]
6. Safety and effectiveness of infliximab for inflammatory bowel diseases in clinical practice.
Tursi A; Elisei W; Brandimarte G; Giorgetti G; Penna A; Castrignano V
Eur Rev Med Pharmacol Sci; 2010 Jan; 14(1):47-55. PubMed ID: 20184089
[TBL] [Abstract][Full Text] [Related]
7. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
Baert F; Noman M; Vermeire S; Van Assche G; D' Haens G; Carbonez A; Rutgeerts P
N Engl J Med; 2003 Feb; 348(7):601-8. PubMed ID: 12584368
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome of newly diagnosed Crohn's disease: a comparative, retrospective study before and after infliximab availability.
Domènech E; Zabana Y; Garcia-Planella E; López San Román A; Nos P; Ginard D; Gordillo J; Martínez-Silva F; Beltrán B; Mañosa M; Cabré E; Gassull MA
Aliment Pharmacol Ther; 2010 Jan; 31(2):233-9. PubMed ID: 19832727
[TBL] [Abstract][Full Text] [Related]
9. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment.
Hyder SA; Travis SP; Jewell DP; McC Mortensen NJ; George BD
Dis Colon Rectum; 2006 Dec; 49(12):1837-41. PubMed ID: 17041753
[TBL] [Abstract][Full Text] [Related]
10. The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease.
Kierkus J; Dadalski M; Szymanska E; Oracz G; Wegner A; Gorczewska M; Szymanska S; Woynarowski M; Ryzko J
Eur J Gastroenterol Hepatol; 2012 May; 24(5):495-500. PubMed ID: 22387887
[TBL] [Abstract][Full Text] [Related]
11. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.
Vermeire S; Louis E; Carbonez A; Van Assche G; Noman M; Belaiche J; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; D'Haens G; Rutgeerts P;
Am J Gastroenterol; 2002 Sep; 97(9):2357-63. PubMed ID: 12358256
[TBL] [Abstract][Full Text] [Related]
12. Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-α agents.
Kestens C; van Oijen MG; Mulder CL; van Bodegraven AA; Dijkstra G; de Jong D; Ponsioen C; van Tuyl BA; Siersema PD; Fidder HH; Oldenburg B;
Clin Gastroenterol Hepatol; 2013 Jul; 11(7):826-31. PubMed ID: 23376000
[TBL] [Abstract][Full Text] [Related]
13. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease.
Rutgeerts P; Diamond RH; Bala M; Olson A; Lichtenstein GR; Bao W; Patel K; Wolf DC; Safdi M; Colombel JF; Lashner B; Hanauer SB
Gastrointest Endosc; 2006 Mar; 63(3):433-42; quiz 464. PubMed ID: 16500392
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.
Vermeire S; Noman M; Van Assche G; Baert F; D'Haens G; Rutgeerts P
Gut; 2007 Sep; 56(9):1226-31. PubMed ID: 17229796
[TBL] [Abstract][Full Text] [Related]
15. Infliximab reintroduction is not associated to a higher rate of immune-related adverse effects in patients with inflammatory bowel disease initially treated with a three-infusion induction regimen.
Domènech E; Zabana Y; Mañosa M; Garcia-Planella E; Cabré E; Gassull MA
J Clin Gastroenterol; 2010 Jan; 44(1):34-7. PubMed ID: 19417683
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up.
Molloy ES; Langford CA; Clark TM; Gota CE; Hoffman GS
Ann Rheum Dis; 2008 Nov; 67(11):1567-9. PubMed ID: 18677012
[TBL] [Abstract][Full Text] [Related]
17. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial.
Van Assche G; Magdelaine-Beuzelin C; D'Haens G; Baert F; Noman M; Vermeire S; Ternant D; Watier H; Paintaud G; Rutgeerts P
Gastroenterology; 2008 Jun; 134(7):1861-8. PubMed ID: 18440315
[TBL] [Abstract][Full Text] [Related]
18. Infliximab maintenance therapy is associated with decreases in direct resource use in patients with luminal or fistulizing Crohn's disease.
Taxonera C; Rodrigo L; Casellas F; Calvet X; Gómez-Camacho F; Ginard D; Castro M; Castro L; Ponce M; Martínez-Montiel P; Ricart E; Gisbert JP; López-San Román A; Morales JM; Casado MA
J Clin Gastroenterol; 2009; 43(10):950-6. PubMed ID: 19448569
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study.
Fidder H; Schnitzler F; Ferrante M; Noman M; Katsanos K; Segaert S; Henckaerts L; Van Assche G; Vermeire S; Rutgeerts P
Gut; 2009 Apr; 58(4):501-8. PubMed ID: 18832524
[TBL] [Abstract][Full Text] [Related]
20. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.
Asteria CR; Ficari F; Bagnoli S; Milla M; Tonelli F
Scand J Gastroenterol; 2006 Sep; 41(9):1064-72. PubMed ID: 16938720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
